From:  Role of cyproheptadine in chronic urticaria not controlled with second-generation antihistamines: a retrospective study

 Outcome parameters at 4 months.

ParametersGroup A (n = 48)Percentage reduction from baseline (group A)Intra-group p-value (group A)Group B (n = 55)Percentage reduction from baseline (group B)Intra-group p-value (group B)Inter-group p-value
4 months UAS710.94 ± 2.28*69.4%< 0.0521.26 ± 3.65*39.9%< 0.05< 0.001
4 months CU-Q2oL36.06 ± 5.94*62.5%< 0.0569.24 ± 13.67*26.5%< 0.05< 0.001
4 months DLQI6.02 ± 1.85*73.7%< 0.0520.24 ± 5.2812.5%< 0.05< 0.001

Group A received cyproheptadine for 1 month + antihistamines; group B received montelukast for 4 months + antihistamines. Both groups continued second-generation antihistamines throughout. *: p < 0.05 corresponding to the baseline values. UAS7: weekly urticaria activity score; CU-Q2oL: chronic urticaria quality of life questionnaire; DLQI: dermatology life quality index.